Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

2013 Archived Content
Seventh Annual

Cancer Molecular Markers

Advancing Personalized Medicine


Day 1 | Day 2 | Day 3 | View TRICON Attendees 

Advances in molecular techniques have made it possible to profile and characterize cancer on a molecular basis. Cancer molecular markers will be compared and evaluated using deep sequencing, cancer stem cells and circulating tumor cells. Molecular markers will be assessed for their potential use in clinical settings. This field is revolutionizing cancer treatment and will lead the way to applying these techniques in other disease areas.

Wednesday, February 13

7:00 am Registration and Morning Coffee


Plenary Keynote Session 

8:00 – 9:40 am Plenary Keynote Presentation - Personalized Oncology – Fulfilling the Promise for Today's Patients

In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs.Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future.

Read more 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing


Keynote Session 

11:00 Chairperson’s Opening Remarks

11:10 Biomarkers in Circulating Tumor Cells: Current Progress toward Qualifying Molecular Assays

Daniel Danila, M.D., Genitourinary Oncology Service, Department of Medicine,Memorial Sloan-Kettering Cancer Center

Unmet needs in cancer drug development and patient management are the ability to monitor treatment benefit and to identify the target of interest in a tumor at the time treatment is being considered. Focusing on molecular biomarkers in CTC, this presentation will emphasize the current state of establishing analytical valid biomarkers for specific contexts of use in patients with castration-resistant prostate cancer.

11:40 Chip-Based Characterization of the Molecular Characteristics of CTCs in Prostate and Lung Cancer

Daniel Haber, M.D., Ph.D., Director, Massachusetts General Hospital Cancer, Center; Isselbacher/Schwartz Professor of Oncology, Harvard Medical School; Investigator, Howard Hughes Medical Institute

12:10 pm Circulating Tumor Cells: Challenges and Perspectives

Klaus Pantel, M.D., Director, Institute of Tumor Biology, UKE

Detection and molecular characterization of circulating tumor cells (CTCs) is one of the most active areas of translational cancer research with more than 400 clinical studies including CTCs as biomarker. Aims of research on CTCs include (i) estimation of the risk for metastatic relapse or metastatic progression (prognostic information); (ii) stratification & real-time monitoring of therapies; (iii) identification of therapeutic targets and resistance mechanisms, and (iv) understanding metastatic development in cancer patients.

Veridex 12:40 Luncheon Presentation I: Characterization of Circulating Tumor Cells With the CellSearch PlatformBrad Foulk, Senior Scientist, Janssen R&D 
Beginning in 2004 the CellSearch platform has been FDA approved to enumerate circulating tumor cells(CTC)in metastatic breast, prostate, and colorectal cancer patients.  Since that time the platform has proven to be a valuable research tool for the characterization of CTCs as well. A review of techniques to characterize CTC by molecular and cellular methods will be presented.

Predictive Bio 1:10 Luncheon Presentation II
Maximizing Clinical Utility of Non-Invasive Biomarkers
Anthony P. Shuber, CTO, Predictive BiosciencesWe have developed a non-invasive multianalyte assay combining DNA and protein markers that simultaneously delivers high sensitivity (high NPV) and specificity (high PPV). This unique combination improves clinical performance and reduce assay complexity and cost.

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing


Getting Personalized Diagnostics Ready for Clinical Use 

2:15 Chairperson’s Remarks

2:20 Implementation of Deep (Next-Gen) Sequencing in a Clinical Lab

Toumy Guettouche, Ph.D., Assistant Professor, Hussman Institute for Human Genomics, Dr. John T. MacDonald Foundation Department of Human Genetics; Director, Genome Technology Assessment and Implementation, Center for Genome Technology; Director, Oncogenomics Core Facility, Sylvester Comprehensive Cancer Center, University of Miami, School of Medicine

The presentation will cover the implementation of deep (next-gen) sequencing in a clinical lab. This includes sample preparation and quality control from different types of starting material (e.g. dried blood spot and formalin fixed paraffin embedded samples) and workflow examples using different types of targeted panels.

2:50 Quality Control Parameters and Software Tools to Enable Clinical Sequencing on High-Performance Sequencing Platforms

Shawn Levy, Ph.D., Faculty Investigator, HudsonAlpha Institute for Biotechnology

This presentation details the use of advanced sample registration and identification capabilities as well as rapid sample contamination screens using inexpensive sequecing tools.  Additionally, software tools to complement existing instrument control software to improve instrument reliability and communication will be described.

3:20 Rapid Whole Genome Sequencing: From DNA to Diagnosis in 50 Hours

Darrell Dinwiddie, Ph.D., Director, Lab Operations, Center for Pediatric Genomic Medicine, Children’s Mercy Hospitals and Clinics

Disease progression in newborns is often fast and heterogeneous, so molecular diagnosis must occur rapidly for relevant clinical decision making. Here, we describe 50-hour differential diagnosis of genetic disorders by whole genome sequencing (WGS), featuring substantially automated bioinformatic analysis.

Genia3:50 Solving the Challenges of DNA Sequencing for Molecular Diagnostics

Stefan Roever, CEO & Founder, Genia Technologies

There is no debate that genetic information is needed to truly realize the promise of personalized medicine.The problem is that today’s DNA sequencers cost anywhere from $50K - $1M, rely on complicated optics, and utilize a complex workflow that does not lend itself to clinical utility.

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall

6:20 Close of Day


Day 1 | Day 2 | Day 3